# Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia

> **NCT05720988** · PHASE1 · WITHDRAWN · sponsor: **Jonsson Comprehensive Cancer Center**

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Azacitidine
- **BIOLOGICAL:** Tagraxofusp-erzs

## Key facts

- **NCT ID:** NCT05720988
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-08-03
- **Primary completion:** 2025-08-03
- **Final completion:** 2026-08-03
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** trial was not opened
- **Last updated:** 2024-03-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05720988

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05720988, "Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05720988. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*